inclusion criteria: 1. able and willing to provide informed consent (patients themselves must provide written informed consent before the performance of any study-related procedures, and surrogate consent by family members, designated legal representatives or caregivers will not be permitted). 2. men and women 18 years of age and older 3. early covid-19, defined as one or more symptom(s) of fever (oral temperature ≥ 100.4 degrees f), cough, or shortness of breath, onset of these symptoms within 72 hours of screening, and confirmation of sars-cov-2 infection by a polymerase chain reaction (pcr)-based or rapid antigen diagnostic. 4. resting spo2 ≥ 96.0% on room air on two successive measurements 5. for women of childbearing potential (women who are not permanently sterile \[documented hysterectomy, bilateral tubal ligation, salpingectomy, or oophorectomy\] or postmenopausal \[12 months with no menses without an alternative medical cause\]) * negative urine pregnancy test at screening * willingness to practice a highly effective method of contraception that includes, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with a postmenopausal partner, monogamous relationship with vasectomized partner, vasectomy, licensed hormonal methods, intrauterine device, or consistent use of a barrier method (eg, condom, diaphragm) with spermicide for 28 days after the last dose of study drug 6. for men with sexual partners of childbearing potential, willingness to practice a highly effective method of contraception, as defined above, for 45 days after the last dose of study drug 7. ability and willingness to comply with all aspects of the study, including reliable internet access, through the entire study period

inclusion criteria: 1. able and willing to provide informed consent (patients themselves must provide written informed consent before the performance of any study-related procedures, and surrogate consent by family members, designated legal representatives or caregivers will not be permitted). 2. men and women 18 years of age and older 3. early covid-19, defined as one or more symptom(s) of fever (oral temperature ≥ 100.4 degrees f), cough, or shortness of breath, onset of these symptoms within 72 hours of screening, and confirmation of sars-cov-2 infection by a polymerase chain reaction (pcr)-based or rapid antigen diagnostic. 4. resting spo2 ≥ 96.0% on room air on two successive measurements 5. for women of childbearing potential (women who are not permanently sterile \[documented hysterectomy, bilateral tubal ligation, salpingectomy, or oophorectomy\] or postmenopausal \[12 months with no menses without an alternative medical cause\]) * negative urine pregnancy test at screening * willingness to practice a highly effective method of contraception that includes, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with a postmenopausal partner, monogamous relationship with vasectomized partner, vasectomy, licensed hormonal methods, intrauterine device, or consistent use of a barrier method (eg, condom, diaphragm) with spermicide for 28 days after the last dose of study drug 6. for men with sexual partners of childbearing potential, willingness to practice a highly effective method of contraception, as defined above, for 45 days after the last dose of study drug 7. ability and willingness to comply with all aspects of the study, including reliable internet access, through the entire study period

inclusion criteria: able and willing to provide informed consent (patients themselves must provide written informed consent before the performance of any study-related procedures, and surrogate consent by family members, designated legal representatives or caregivers will not be permitted). men and women 18 years of age and older early covid-19, defined as one or more symptom(s) of fever (oral temperature ≥ 100.4 degrees f), cough, or shortness of breath, onset of these symptoms within 72 hours of screening, and confirmation of sars-cov-2 infection by a polymerase chain reaction (pcr)-based or rapid antigen diagnostic. resting spo2 ≥ 96.0% on room air on two successive measurements for women of childbearing potential (women who are not permanently sterile [documented hysterectomy, bilateral tubal ligation, salpingectomy, or oophorectomy] or postmenopausal [12 months with no menses without an alternative medical cause]) negative urine pregnancy test at screening willingness to practice a highly effective method of contraception that includes, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with a postmenopausal partner, monogamous relationship with vasectomized partner, vasectomy, licensed hormonal methods, intrauterine device, or consistent use of a barrier method (eg, condom, diaphragm) with spermicide for 28 days after the last dose of study drug for men with sexual partners of childbearing potential, willingness to practice a highly effective method of contraception, as defined above, for 45 days after the last dose of study drug ability and willingness to comply with all aspects of the study, including reliable internet access, through the entire study period

inclusion criteria: able and willing to provide informed consent (patients themselves must provide written informed consent before the performance of any study-related procedures, and surrogate consent by family members, designated legal representatives or caregivers will not be permitted). men and women 18 years of age and older early covid-19, defined as one or more symptom(s) of fever (oral temperature ≥ 100.4 degrees f), cough, or shortness of breath, onset of these symptoms within 72 hours of screening, and confirmation of sars-cov-2 infection by a polymerase chain reaction (pcr)-based or rapid antigen diagnostic. resting spo2 ≥ 96.0% on room air on two successive measurements for women of childbearing potential (women who are not permanently sterile [documented hysterectomy, bilateral tubal ligation, salpingectomy, or oophorectomy] or postmenopausal [12 months with no menses without an alternative medical cause]) negative urine pregnancy test at screening willingness to practice a highly effective method of contraception that includes, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with a postmenopausal partner, monogamous relationship with vasectomized partner, vasectomy, licensed hormonal methods, intrauterine device, or consistent use of a barrier method (eg, condom, diaphragm) with spermicide for 28 days after the last dose of study drug for men with sexual partners of childbearing potential, willingness to practice a highly effective method of contraception, as defined above, for 45 days after the last dose of study drug ability and willingness to comply with all aspects of the study, including reliable internet access, through the entire study period

inclusion criteria: 1. able and willing to provide informed consent (patients themselves must provide written informed consent before the performance of any study-related procedures, and surrogate consent by family members, designated legal representatives or caregivers will not be permitted). 2. men and women 18 years of age and older 3. early covid-19, defined as one or more symptom(s) of fever (oral temperature ≥ 100.4 degrees f), cough, or shortness of breath, onset of these symptoms within 72 hours of screening, and confirmation of sars-cov-2 infection by a polymerase chain reaction (pcr)-based or rapid antigen diagnostic. 4. resting spo2 ≥ 96.0% on room air on two successive measurements 5. for women of childbearing potential (women who are not permanently sterile [documented hysterectomy, bilateral tubal ligation, salpingectomy, or oophorectomy] or postmenopausal [12 months with no menses without an alternative medical cause]) - negative urine pregnancy test at screening - willingness to practice a highly effective method of contraception that includes, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with a postmenopausal partner, monogamous relationship with vasectomized partner, vasectomy, licensed hormonal methods, intrauterine device, or consistent use of a barrier method (eg, condom, diaphragm) with spermicide for 28 days after the last dose of study drug 6. for men with sexual partners of childbearing potential, willingness to practice a highly effective method of contraception, as defined above, for 45 days after the last dose of study drug 7. ability and willingness to comply with all aspects of the study, including reliable internet access, through the entire study period

inclusion criteria: 1. able and willing to provide informed consent (patients themselves must provide written informed consent before the performance of any study-related procedures, and surrogate consent by family members, designated legal representatives or caregivers will not be permitted). 2. men and women 18 years of age and older 3. early covid-19, defined as one or more symptom(s) of fever (oral temperature ≥ 100.4 degrees f), cough, or shortness of breath, onset of these symptoms within 72 hours of screening, and confirmation of sars-cov-2 infection by a polymerase chain reaction (pcr)-based or rapid antigen diagnostic. 4. resting spo2 ≥ 96.0% on room air on two successive measurements 5. for women of childbearing potential (women who are not permanently sterile [documented hysterectomy, bilateral tubal ligation, salpingectomy, or oophorectomy] or postmenopausal [12 months with no menses without an alternative medical cause]) - negative urine pregnancy test at screening - willingness to practice a highly effective method of contraception that includes, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with a postmenopausal partner, monogamous relationship with vasectomized partner, vasectomy, licensed hormonal methods, intrauterine device, or consistent use of a barrier method (eg, condom, diaphragm) with spermicide for 28 days after the last dose of study drug 6. for men with sexual partners of childbearing potential, willingness to practice a highly effective method of contraception, as defined above, for 45 days after the last dose of study drug 7. ability and willingness to comply with all aspects of the study, including reliable internet access, through the entire study period